- Home
- SATL vs ALXO Comparison
SATL vs ALXO Comparison
Compare SATL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- ALXO
- Stock Information
- Founded
- SATL 2010
- ALXO 2015
- Country
- SATL Uruguay
- ALXO United States
- Employees
- SATL N/A
- ALXO N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- SATL Technology
- ALXO Health Care
- Exchange
- SATL Nasdaq
- ALXO Nasdaq
- Market Cap
- SATL 91.1M
- ALXO 81.1M
- IPO Year
- SATL N/A
- ALXO 2020
- Fundamental
- Price
- SATL $1.01
- ALXO $1.50
- Analyst Decision
- SATL
- ALXO Strong Buy
- Analyst Count
- SATL 0
- ALXO 6
- Target Price
- SATL N/A
- ALXO $14.20
- AVG Volume (30 Days)
- SATL 45.4K
- ALXO 556.1K
- Earning Date
- SATL 10-29-2024
- ALXO 11-11-2024
- Dividend Yield
- SATL N/A
- ALXO N/A
- EPS Growth
- SATL N/A
- ALXO N/A
- EPS
- SATL N/A
- ALXO N/A
- Revenue
- SATL $13,719,000.00
- ALXO N/A
- Revenue This Year
- SATL N/A
- ALXO N/A
- Revenue Next Year
- SATL N/A
- ALXO N/A
- P/E Ratio
- SATL N/A
- ALXO N/A
- Revenue Growth
- SATL 101.51
- ALXO N/A
- 52 Week Low
- SATL $0.69
- ALXO $1.42
- 52 Week High
- SATL $2.52
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- SATL 50.18
- ALXO 31.29
- Support Level
- SATL $0.97
- ALXO $1.43
- Resistance Level
- SATL $1.02
- ALXO $1.62
- Average True Range (ATR)
- SATL 0.04
- ALXO 0.11
- MACD
- SATL 0.00
- ALXO 0.03
- Stochastic Oscillator
- SATL 52.94
- ALXO 19.51
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.